News
ITRMF
0.024
-11.11%
-0.003
Weekly Report: what happened at ITRMF last week (0713-0717)?
Weekly Report · 1d ago
Weekly Report: what happened at ITRMF last week (0706-0710)?
Weekly Report · 07/13 09:28
Weekly Report: what happened at ITRMF last week (0629-0703)?
Weekly Report · 07/06 09:29
Weekly Report: what happened at ITRMF last week (0622-0626)?
Weekly Report · 06/29 09:27
Weekly Report: what happened at ITRMF last week (0615-0619)?
Weekly Report · 06/22 09:31
Weekly Report: what happened at ITRMF last week (0608-0612)?
Weekly Report · 06/15 09:31
Weekly Report: what happened at ITRMF last week (0601-0605)?
Weekly Report · 06/08 09:29
Weekly Report: what happened at ITRMF last week (0525-0529)?
Weekly Report · 06/01 09:31
Weekly Report: what happened at ITRMF last week (0518-0522)?
Weekly Report · 05/25 09:33
Weekly Report: what happened at ITRMF last week (0511-0515)?
Weekly Report · 05/18 09:32
Weekly Report: what happened at ITRMF last week (0504-0508)?
Weekly Report · 05/11 09:31
Weekly Report: what happened at ITRMF last week (0427-0501)?
Weekly Report · 05/04 09:30
Weekly Report: what happened at ITRMF last week (0420-0424)?
Weekly Report · 04/27 09:31
Weekly Report: what happened at ITRMF last week (0413-0417)?
Weekly Report · 04/20 09:30
Eton Pharma drops after CFO succession plan
Seeking Alpha · 04/16 17:03
Weekly Report: what happened at ITRMF last week (0406-0410)?
Weekly Report · 04/13 09:31
Weekly Report: what happened at ITRMF last week (0330-0403)?
Weekly Report · 04/06 09:31
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 03/31 21:05
Iterum Therapeutics shares face Nasdaq delisting after minimum bid price breach
Reuters · 03/31 20:59
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 03/31 17:05
More
Webull provides a variety of real-time ITRMF stock news. You can receive the latest news about Iterum Therapeutics Plc through multiple platforms. This information may help you make smarter investment decisions.
About ITRMF
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives. It offers ORLYNVAH (oral sulopenem) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections (uUTIs) caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belongs to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The Company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.